US Product Portfolio for Dental Bone Graft Substitutes and Other Biomaterials 2017 – MedFolio

US Product Portfolio for Dental Bone Graft Substitutes and Other Biomaterials 2017 – MedFolio

0

  • Year: 2017
  • Scope: 2013-2023
  • Region: United States
  • Published Date: 7/1/2017
  • Pages: 206
  • Type: MedFolio

The full report suite on the U.S. market for dental bone graft substitutes (DBGS) and other biomaterials includes dental bone graft substitutes, dental growth factors and dental barrier membranes.

General Report Contents
– Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
– Market Drivers & Limiters for each chapter segment
– Competitive Analysis for each chapter segment
– Section on recent mergers & acquisitions
A major limiter preventing market growth in the dental bone graft substitute and other biomaterials markets is the tendency to supplement large-scale implant purchases with discounted, and even complimentary, DBGS materials. As periodontists and oral surgeons outnumber general practitioners (GPs) in terms of dentists placing implants in the United States, and as these specialists tend to buy in bulk, this trend is expected to persist in the future.

The growing number of GPs placing implants is driving the total markets for dental bone graft substitutes and other biomaterials forward by increasing the volume of dental implant procedures. Another result of more GPs trained on implants is that they are more knowledgeable over the critical factors necessary to achieve a successful implant procedure. Therefore, the increased number of GPs placing implants increases the probability that a patient is informed on the importance of having a sufficient level of bone in their jaw prior to the procedure. Ultimately, this will result in a greater number of patient referrals to specialists for dental regenerative procedures that incorporate either a DBGS and membrane or a dental growth factor.

As in previous years, pre-existing materials within the market continue to be improved. Improvements are being made to every segment of the DBGS market. With regards to digital systems, the high growth rate of the dental implant industry has spurred the development and greater acceptance of technologies in the dental market that assist in greater efficiency in restoring dental implants; these technological advances, in turn, drive further placement of implants as they offer dentists greater assistance. The greater utilization of cone beam computed tomography (CBCT) scanners, which are modified versions of traditional CT scanners for dental applications, assists in designing accurate three-dimensional models of a patient’s jaw. Based on the three-dimensional model, imaging software can be used to diagnose the bone density and structure of the patient’s jaw structure that will provide much greater insight into the condition of the patient’s jaw. With regards to dental growth factors, the market is moving towards improving the convenience of handling the products. Handling characteristics are essential features of dental growth factor products. Due to their chemical and biological composition, these products are easier to apply than conventional bone graft materials. These products are often provided in a liquid format, allowing them to be combined with bone graft substitutes by end-users to suit their purposes. The current exception to this is Osteocel®, which must be kept frozen until ready for use.



The "US Market Report Suite for Dental Bone Graft Substitutes 2017 - MedSuite" includes analysis on the following companies currently active in this market:
Geistlich
Zimmer Biomet
ACE Surgical
BioHorizons
Tissue Banks
Osteogenics
LifeNet Health
Dentsply Sirona
Salvin
Straumann
Osteohealth
Keystone Dental
Others include: AB Dental, Benco, Bicon, BTI, Collagen Matrix, Cortex Dental, Curasan, Datum Dental, Dentium USA, Dyna Dental, Henry Schein, Impladent LTD, Implant Direct, Inion, KaVo Kerr, Keystone Dental, LifeNet Health, MegaGen, MIS Implants, Nobel Biocare, NovaBone, Osteogenics, Osteohealth, Patterson, Regenetix, Snoasis Medical, Straumann, Unicare Biomedical, etc.
*Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.




Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology

Thank you!

CLOSE
Report Type Info

Single License: A single license is for use by a single individual only. Usage rights may not be transferred, sold or distributed by any means.

Site License: A site license allows sharing of the reports between various users within the purchasing company’s designated business address within this agreement.

Corporate License: A corporate license is for the use of one corporation. A corporation is defined as any business entity incorporated under a single name. Separate corporations operating under the same parent company are not included in this license.

Executive Summary: An in-depth summary of the reports associated with the related MedSuite product.

CLOSE

Login

Sign Up

Already have an account? Sign in

×